Aurorus 2026 B.V.: 20 October 2026

A Dutch consumer loan securitisation originated by Buy Way Personal Finance B.V. (formerly Qander Consumer Finance B.V.), where the Issuer will make payments on the Notes from, among other things, payments of principal and interest received from a portfolio comprising consumer loan receivables originated in the Netherlands. The portfolio includes fixed-rate and floating-rate amortising loans, together with fixed-rate and floating-rate revolving credit facilities.

As at the final portfolio cut-off date (30 September 2026), the pool consisted of 28,765 loan contracts, with an aggregate outstanding principal balance of EUR398.01 million. The average current loan balance was EUR13,837.

Portfolio Characteristics (by outstanding balance): Fixed-Rate Amortising – 93.44%, Fixed-Rate Revolving – 0.65%, Floating-Rate Amortising – 3.35% and Floating-Rate Revolving – 2.56%. The weighted-average interest rate was 8.42%, the weighted-average minimum payment rate was 1.94% and the weighted-average seasoning was 2.42 years. The weighted-average remaining term for the fixed-rate amortising portfolio was 84.20 months. The maximum outstanding loan balance was EUR75,000.

EU & UK Risk Retention: Buy Way Personal Finance B.V., as Seller and originator, has undertaken to retain, on an ongoing basis, a material net economic interest of not less than 5% in accordance with Article 6(1) and Article 6(3)(a) of the EU Securitisation Regulation. The Seller will retain at least 5% of the principal amount outstanding of each Class of Asset-Backed Notes. The Seller has also undertaken, on a contractual basis, to comply with the applicable UK risk retention requirements, including SECN 5.2.8R(1)(a) of the FCA Handbook.

US Risk Retention: The transaction will not involve risk retention by the Seller or any other party under the US Risk Retention Rules. Instead, the transaction will rely on the exemption for non-US transactions provided under Section 20 of the US Risk Retention Rules. This exemption is subject to certain conditions, including a restriction that no more than 10% of the aggregate value of all classes of securities issued in the securitisation may be sold or transferred to US persons, or for their account or benefit.